Flagship Pioneering, LLC
An institutional investment manager in CAMBRIDGE, MA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1400240.
- Reported value$1.54bn
- Positions5
Holdings: 5 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31. The filing's table has 7 lines; lines for the same security and option type are added together here.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Generate Biomedicines IncGENB | COM SHS | 370920100 | 1,057 | 68.7% | 62,673,117 | Unchanged | |
| Moderna IncMRNA | COM | 60770K107 | 324 | 21.1% | 4,632,149 | Unchanged | |
| Sana Biotechnology IncSANA | COM | 799566104 | 87.3 | 5.7% | 25,001,856 | Unchanged | |
| Foghorn Therapeutics IncFHTX | COM | 344174107 | 61.8 | 4.0% | 12,674,120 | Unchanged | |
| Seres Therapeutics IncMCRB | COM NEW | 81750R201 | 9.1 | 0.6% | 1,155,850 | Unchanged |
Source: SEC EDGAR, Form 13F-HR, accession 0001193125-26-352122 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.